Use of intravenous bisphosphonates in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems

Abstract

Almost one half of all patients with BM due to BC, and substantially more with LC and PC, do not receive IV bisphosphonates. Among patients receiving such therapy, treatment often is not initiated until after the occurrence of an SRE. Our study suggests that IV bisphosphonates may be substantially underutilized in patients with BM due to these common cancers.

Increased Frequencies of Circulating IFN-γ-Producing Vδ1+and Vδ2+γδ T Cells in Patients with Asymptomatic Persistent Hepatitis B Virus Infection

“…Their multifunctional capacity makes them ideal candidates for immunotherapy, and they are already the focus of several clinical trials (5,12,20,42,51). Vd1 T cells are mainly found at mucosal surfaces and can exhibit immunostimulatory (26,29) and immunoregulatory (6) functions and are also under consideration as therapeutic targets (49).…”

“…These findings implicate Vd2 T cells as key players in the control of HBV replication, most likely via the production of IFN-c. Since Vd2 T cells have already been identified as targets for immunotherapy and they are already the focus of several clinical trials (5,12,20,42,51), it is proposed that they might be used as the basis for future immunotherapies to treat HBV patients with persistent symptomatic infection.…”

Longitudinal patterns of bone-targeted agent use among patients with solid tumors and bone metastases in the United States

“…Although two recent administrative claim based studies have examined treatment patterns for IV BP in solid tumor patients beyond 1 year [19, 20], the only study to include all available treatment options reported BTA treatment patterns observed in the Oncology Services Comprehensive Electronic Records (OSCER) for patients with solid tumors whose first bone metastasis was diagnosed in 2011, with a maximum of 12-month follow-up [18]. The current study adds to these previously reported results by examining BTA treatment patterns for the two most commonly used agents, denosumab and zoledronic acid, over up to 3 years of follow-up.…”

“…However, this finding should be interpreted with caution. As Oster et al note, SREs may be the catalyst for the initiation of BTA therapy, since in that study, similar percentages of breast cancer and prostate cancer patients initiated IV BP prior to and after experiencing their first skeletal complication [19]. Furthermore, the recording of bone metastasis diagnosis may commonly be delayed until treatment is initiated.…”

Beyond the Vascular Endothelial Growth Factor Axis: Update on Role of Imaging in Nonantiangiogenic Molecular Targeted Therapies in Oncology

“…Bisphosphonate therapy is recommended in patients with osteoporosis (T score < −2.5) and should be considered for patients with osteopenia (T score < −1). Bisphosphonates have become important in many cancers to prevent skeletal-related adverse events, with pamidronate approved in 1996 for use in patients with osteolytic metastases from breast cancer and multiple myeloma, and zoledronic acid approved in 2001 for the treatment of bone metastases from solid tumors as well as multiple myeloma [62,63]. Adverse effects of bisphosphonates include gastrointestinal and renal toxicity, osteonecrosis of the jaw, and atypical fractures of the lateral subtrochanteric diaphyseal femur that occur with minimal or no trauma [61,64] (Fig.…”